Pfizer: Q4 EPS up more than six-fold

(CercleFinance.com) - Pfizer has announced adjusted EPS of $0.
63 for the Q4 2024, compared with $0.10 a year ago, on revenues up 22% to nearly $17.8bn (+21% on an operating basis, including +11% excluding Covid-19 products). NB: cp +2%.

The pharmaceutical giant confirms its targets for 2025, i.e. adjusted EPS of $2.80 to $3, as well as revenues of $61bn to $64bn, compared with adjusted EPS of $3.11 and revenues of $63.6bn achieved over FY 2024.

In addition, Pfizer says it has achieved its target of $4bn in net cost savings under its cost realignment program, and has increased its total target to around $4.5bn by the end of the current year.


Copyright (c) 2025 CercleFinance.com. All rights reserved.